Literature DB >> 11192347

Treatment of heart failure with beta-blockers. Mechanisms and results.

M Böhm1, C Maack.   

Abstract

Sympathetic activation is a significant predictor of a poor prognosis in heart failure. Excessive stimulation with norepinephrine produces apoptosis, tachycardia and arrhythmias thereby leading to progression of left ventricular dysfunction and worsening of outcome. Beta-blockers reduce morbidity and improve cardiac function. They have been shown to improve survival (MERIT-HF, CIBIS II and US-Carvedilol Trials). A careful uptitration of dosages is achievable with a low rate of side effects. The mechanism of beta-blocker effects in heart failure are cardiac protection from beta1-adrenoceptor overstimulation, antiarrhythmic effects, reduction in heart rate and positive energetic effects or a combination thereof.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11192347     DOI： 10.1007/s003950070004

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN： 0300-8428            Impact factor:   17.165


  10 in total

1.  [Hemodynamic effects of the beta blocker nebivolol].

Authors:  S Rosenkranz; E Erdmann
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

2.  The expression level of ecto-NTP diphosphohydrolase1/CD39 modulates exocytotic and ischemic release of neurotransmitters in a cellular model of sympathetic neurons.

Authors:  Federico Corti; Kim E Olson; Aaron J Marcus; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2011-02-16       Impact factor: 4.030

Review 3.  BNP and Heart Failure: Preclinical and Clinical Trial Data.

Authors:  Emmanuel E Egom
Journal:  J Cardiovasc Transl Res       Date:  2015-03-14       Impact factor: 4.132

Review 4.  A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches.

Authors:  Vivek Sarohi; Shriya Srivastava; Trayambak Basak
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-01

5.  Cellular responses to in vitro exposures to β-blocking pharmaceuticals in hard clams and Eastern oysters.

Authors:  Bushra Khan; Robert M Burgess; Sandra A Fogg; Mark G Cantwell; David R Katz; Kay T Ho
Journal:  Chemosphere       Date:  2018-07-27       Impact factor: 7.086

Review 6.  Myofilament dysfunction in cardiac disease from mice to men.

Authors:  Nazha Hamdani; Monique de Waard; Andrew E Messer; Nicky M Boontje; Viola Kooij; Sabine van Dijk; Amanda Versteilen; Regis Lamberts; Daphne Merkus; Cris Dos Remedios; Dirk J Duncker; Attila Borbely; Zoltan Papp; Walter Paulus; Ger J M Stienen; Steven B Marston; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2009-01-13       Impact factor: 2.698

7.  More severe cellular phenotype in human idiopathic dilated cardiomyopathy compared to ischemic heart disease.

Authors:  Nazha Hamdani; Attila Borbély; Sophie P G R Veenstra; Viola Kooij; Wim Vrydag; Ruud Zaremba; Cris Dos Remedios; Hans W M Niessen; Martin C Michel; Walter J Paulus; Ger J M Stienen; Jolanda van der Velden
Journal:  J Muscle Res Cell Motil       Date:  2010-12-04       Impact factor: 2.698

Review 8.  Cellular and Molecular Mechanism of Traditional Chinese Medicine on Ventricular Remodeling.

Authors:  Yong-Chun Zhu; Bo Liang; Ning Gu
Journal:  Front Cardiovasc Med       Date:  2021-12-01

Review 9.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  Dynamics of adrenergic signaling in cardiac myocytes and implications for pharmacological treatment.

Authors:  Emily E Meyer; Colleen E Clancy; Timothy J Lewis
Journal:  J Theor Biol       Date:  2021-03-16       Impact factor: 2.691
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.